A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH)
Completed · Phase 4 · NCT05564039
Conditions: Type 2 Diabetes
At a glance
- Research payments reported, 2025
- $41,779
- U.S. investigators named
- 6
- Sites paid
- 6
- Planned or actual enrollment
- 282
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- Tirzepatide (drug), Dulaglutide (drug)
- Dates
- Started 2022-11-30; completion 2024-08-12
- Results posted
- Yes
The main purpose of this study is to investigate the efficacy and safety of switching from weekly dulaglutide to weekly tirzepatide compared to increasing the dulaglutide dose in adults with type 2 diabetes.
From ClinicalTrials.gov, last updated 2025-08-03. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $41,779 in research payments for this study in 2025 (6 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Lorena Lewy Alterbaum, MD Endocrinology & Diabetes · Hollywood, FL
- Anuj Bhargava, MD Endocrinology & Diabetes · West Des Moines, IA
- David G. True, D.O. Rheumatology · Nixa, MO
- Lisa B. Connery, M.D. Family Medicine · Norman, OK
- John D. Gabriel, MD Family Medicine · North Richland Hills, TX
- Agadadash Kuliev, MD Internal Medicine · Houston, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Clinvest Headlands LLC $17,199
- All Medical Research LLC $14,486
- Iowa Diabetes and Endocrinology Rsrch Cntr $5,600
- Biopharma Informatic Inc $3,400
- Alliance for Multispecialty Research Lls $645
- North Hills Medical Research $450
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.